Boston Scientific to Acquire Penumbra for $14.5 Billion, Expanding Cardiovascular and Neurovascular Portfolio
Summary
Boston Scientific announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion in cash and stock, significantly expanding its presence in mechanical thrombectomy and neurovascular markets.
Key Events
-
Acquisition Agreement
Boston Scientific will acquire Penumbra, Inc. for an enterprise value of approximately $14.5 billion.
-
Strategic Expansion
The acquisition provides scaled entry into mechanical thrombectomy and neurovascular, expanding Boston Scientific's cardiovascular portfolio into high-growth adjacent areas.
-
Transaction Details
The deal is structured as a cash and stock transaction (73% cash, 27% stock), with Boston Scientific financing the $11 billion cash portion through a combination of cash on hand and new debt.
-
Financial Impact
The transaction is expected to be dilutive to adjusted EPS by $0.06-$0.08 in the first full year post-close, becoming neutral to slightly accretive in the second year and more accretive thereafter.
Analysis
This major acquisition positions Boston Scientific for long-term growth by entering new, fast-growing segments within the vascular space, including mechanical thrombectomy and neurovascular. While the transaction is expected to be dilutive to adjusted earnings per share in the first year, the strategic benefits of a diversified portfolio and enhanced market access are substantial. The deal represents a significant strategic move to address the increasing prevalence of vascular diseases globally.
At the time of this filing, BSX was trading at $89.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $139B. The 52-week trading range was $85.98 to $109.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.